Literature DB >> 25736419

Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.

Marilyn H Perrin1, Laura A Tan1, Joan M Vaughan1, Kathy A Lewis1, Cynthia J Donaldson1, Charleen Miller1, Judit Erchegyi1, Jean E Rivier1, Paul E Sawchenko2.   

Abstract

The corticotropin-releasing factor (CRF) peptide family comprises the mammalian peptides CRF and the urocortins as well as frog skin sauvagine and fish urophyseal urotensin. Advances in understanding the roles of the CRF ligand family and associated receptors have often relied on radioreceptor assays using labeled CRF ligands. These assays depend on stable, high-affinity CRF analogs that can be labeled, purified, and chemically characterized. Analogs of several of the native peptides have been used in this context, most prominently including sauvagine from the frog Phyllomedusa sauvageii (PS-Svg). Because each of these affords both advantages and disadvantages, new analogs with superior properties would be welcome. We find that a sauvagine-like peptide recently isolated from a different frog species, Pachymedusa dacnicolor (PD-Svg), is a high-affinity agonist whose radioiodinated analog, [(125)ITyr(0)-Glu(1), Nle(17)]-PD-Svg, exhibits improved biochemical properties over those of earlier iodinated agonists. Specifically, the PD-Svg radioligand binds both CRF receptors with comparably high affinity as its PS-Svg counterpart, but detects a greater number of sites on both type 1 and type 2 receptors. PD-Svg is also ∼10 times more potent at stimulating cAMP accumulation in cells expressing the native receptors. Autoradiographic localization using the PD-Svg radioligand shows robust specific binding to rodent brain and peripheral tissues that identifies consensus CRF receptor-expressing sites in a greater number and/or with greater sensitivity than its PS-Svg counterpart. We suggest that labeled analogs of PD-Svg may be useful tools for biochemical, structural, pharmacological, and anatomic studies of CRF receptors.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25736419      PMCID: PMC4407721          DOI: 10.1124/jpet.114.222307

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  50 in total

1.  Kinetics of peptide binding to the class II MHC protein I-Ek.

Authors:  P M Kasson; J D Rabinowitz; L Schmitt; M M Davis; H M McConnell
Journal:  Biochemistry       Date:  2000-02-08       Impact factor: 3.162

2.  Constitutive activation of tethered-peptide/corticotropin-releasing factor receptor chimeras.

Authors:  S M Nielsen; L Z Nielsen; S A Hjorth; M H Perrin; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

3.  Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

Authors:  K H Skelton; C B Nemeroff; D L Knight; M J Owens
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

4.  Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress.

Authors:  T L Bale; A Contarino; G W Smith; R Chan; L H Gold; P E Sawchenko; G F Koob; W W Vale; K F Lee
Journal:  Nat Genet       Date:  2000-04       Impact factor: 38.330

5.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

6.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 7.  Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression.

Authors:  Johannes M H M Reul; Florian Holsboer
Journal:  Curr Opin Pharmacol       Date:  2002-02       Impact factor: 5.547

8.  Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse.

Authors:  K Van Pett; V Viau; J C Bittencourt; R K Chan; H Y Li; C Arias; G S Prins; M Perrin; W Vale; P E Sawchenko
Journal:  J Comp Neurol       Date:  2000-12-11       Impact factor: 3.215

9.  Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala.

Authors:  Vaishali P Bakshi; Stephanie Smith-Roe; Sarah M Newman; Dimitri E Grigoriadis; Ned H Kalin
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

10.  The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.

Authors:  A J Lawrence; E V Krstew; F M Dautzenberg; A Rühmann
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more
  1 in total

1.  Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).

Authors:  Judit Erchegyi; Lixin Wang; Jozsef Gulyas; Manoj Samant; Marilyn H Perrin; Kathy Lewis; Charleen Miller; Joan Vaughan; Cynthia Donaldson; Wolfgang Fischer; William Low; Seiichi Yakabi; Hiroshi Karasawa; Yvette Taché; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2016-02-03       Impact factor: 7.446

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.